What is the projected market valuation for the Dry Age-Related Macular Degeneration Market in 2035?

The projected market valuation for the Dry Age-Related Macular Degeneration Market in 2035 is 11.44 USD Billion. Read More

What was the market valuation for the Dry Age-Related Macular Degeneration Market in 2024?

The market valuation for the Dry Age-Related Macular Degeneration Market in 2024 was 4.76 USD Billion. Read More

What is the expected CAGR for the Dry Age-Related Macular Degeneration Market from 2025 to 2035?

The expected CAGR for the Dry Age-Related Macular Degeneration Market during the forecast period 2025 - 2035 is 8.3%. Read More

Which age group shows the highest market valuation for Dry Age-Related Macular Degeneration?

The age group above 75 years shows the highest market valuation, projected at 4.5 USD Billion. Read More

What are the key segments of the Dry Age-Related Macular Degeneration Market?

Key segments include stages of the disease, age groups, routes of administration, and end users. Read More

Which route of administration is expected to have the highest market valuation?

Injectables are expected to have the highest market valuation, projected at 6.94 USD Billion. Read More

Who are the leading companies in the Dry Age-Related Macular Degeneration Market?

Leading companies include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Apellis Pharmaceuticals. Read More

How does the market valuation for Late Age-Related Macular Degeneration compare to Early Age-Related Macular Degeneration?

In 2035, Late Age-Related Macular Degeneration is projected at 2.52 USD Billion, compared to 3.36 USD Billion for Early Age-Related Macular Degeneration. Read More

What is the expected market valuation for hospitals and clinics as end users in 2035?

The expected market valuation for hospitals and clinics as end users in 2035 is 4.5 USD Billion. Read More

Dry Age-Related Macular Degeneration AMD Market

Q: What is the projected market valuation for Intermediate Age-Related Macular Degeneration in 2035?

The projected market valuation for Intermediate Age-Related Macular Degeneration in 2035 is 5.56 USD Billion. Read More

Global Dry Age-Related Macular Degeneration Market Research Report Information By Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, and Above 40 Years), By Diagnosis and Treatment (Treatment and Diagnosis), By Route of Administration (Oral and Injectables), By End Users (Hospitals & Clinics, Diagnostic Centers, and Academic & Research Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035.

Forecast Period

2025 - 2035

CAGR

8.3%

2024 Market Size

$ 4.76 Billion

2035 Market Size

$ 11.44 Billion

Life Sciences ● Updated August 2026 Report ID: MRFR/LS/9174-CR | Pages: 171 | Author: Vikita Thakur, Kinjoll Dey

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Stages (USD Billion)
  1. 4.1.1 Early Age-Related Macular Degeneration
  2. 4.1.2 Intermediate Age-Related Macular Degeneration
  3. 4.1.3 Late Age-Related Macular Degeneration
2. 4.2 Healthcare, BY Age Group (USD Billion)
  1. 4.2.1 Above 75 Years
  2. 4.2.2 Above 60 Years
  3. 4.2.3 Above 40 Years
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Injectables
4. 4.4 Healthcare, BY End Users (USD Billion)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Academic & Research Institutes
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Regeneron Pharmaceuticals (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Apellis Pharmaceuticals (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Horizon Therapeutics (IE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Santen Pharmaceutical (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Alcon (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Zeiss (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY STAGES
4. 6.4 US MARKET ANALYSIS BY AGE GROUP
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY END USERS
7. 6.7 CANADA MARKET ANALYSIS BY STAGES
8. 6.8 CANADA MARKET ANALYSIS BY AGE GROUP
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY END USERS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY STAGES
13. 6.13 GERMANY MARKET ANALYSIS BY AGE GROUP
14. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
15. 6.15 GERMANY MARKET ANALYSIS BY END USERS
16. 6.16 UK MARKET ANALYSIS BY STAGES
17. 6.17 UK MARKET ANALYSIS BY AGE GROUP
18. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
19. 6.19 UK MARKET ANALYSIS BY END USERS
20. 6.20 FRANCE MARKET ANALYSIS BY STAGES
21. 6.21 FRANCE MARKET ANALYSIS BY AGE GROUP
22. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
23. 6.23 FRANCE MARKET ANALYSIS BY END USERS
24. 6.24 RUSSIA MARKET ANALYSIS BY STAGES
25. 6.25 RUSSIA MARKET ANALYSIS BY AGE GROUP
26. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
27. 6.27 RUSSIA MARKET ANALYSIS BY END USERS
28. 6.28 ITALY MARKET ANALYSIS BY STAGES
29. 6.29 ITALY MARKET ANALYSIS BY AGE GROUP
30. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 ITALY MARKET ANALYSIS BY END USERS
32. 6.32 SPAIN MARKET ANALYSIS BY STAGES
33. 6.33 SPAIN MARKET ANALYSIS BY AGE GROUP
34. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
35. 6.35 SPAIN MARKET ANALYSIS BY END USERS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY STAGES
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USERS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY STAGES
42. 6.42 CHINA MARKET ANALYSIS BY AGE GROUP
43. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
44. 6.44 CHINA MARKET ANALYSIS BY END USERS
45. 6.45 INDIA MARKET ANALYSIS BY STAGES
46. 6.46 INDIA MARKET ANALYSIS BY AGE GROUP
47. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
48. 6.48 INDIA MARKET ANALYSIS BY END USERS
49. 6.49 JAPAN MARKET ANALYSIS BY STAGES
50. 6.50 JAPAN MARKET ANALYSIS BY AGE GROUP
51. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 JAPAN MARKET ANALYSIS BY END USERS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY STAGES
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USERS
57. 6.57 MALAYSIA MARKET ANALYSIS BY STAGES
58. 6.58 MALAYSIA MARKET ANALYSIS BY AGE GROUP
59. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USERS
61. 6.61 THAILAND MARKET ANALYSIS BY STAGES
62. 6.62 THAILAND MARKET ANALYSIS BY AGE GROUP
63. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
64. 6.64 THAILAND MARKET ANALYSIS BY END USERS
65. 6.65 INDONESIA MARKET ANALYSIS BY STAGES
66. 6.66 INDONESIA MARKET ANALYSIS BY AGE GROUP
67. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
68. 6.68 INDONESIA MARKET ANALYSIS BY END USERS
69. 6.69 REST OF APAC MARKET ANALYSIS BY STAGES
70. 6.70 REST OF APAC MARKET ANALYSIS BY AGE GROUP
71. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USERS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY STAGES
75. 6.75 BRAZIL MARKET ANALYSIS BY AGE GROUP
76. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 BRAZIL MARKET ANALYSIS BY END USERS
78. 6.78 MEXICO MARKET ANALYSIS BY STAGES
79. 6.79 MEXICO MARKET ANALYSIS BY AGE GROUP
80. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
81. 6.81 MEXICO MARKET ANALYSIS BY END USERS
82. 6.82 ARGENTINA MARKET ANALYSIS BY STAGES
83. 6.83 ARGENTINA MARKET ANALYSIS BY AGE GROUP
84. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USERS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGES
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USERS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY STAGES
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USERS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY STAGES
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USERS
99. 6.99 REST OF MEA MARKET ANALYSIS BY STAGES
100. 6.100 REST OF MEA MARKET ANALYSIS BY AGE GROUP
101. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USERS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY STAGES, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY STAGES, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USERS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USERS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.2.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USERS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.3.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USERS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.4.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USERS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.5.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USERS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.6.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USERS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.7.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USERS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.8.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USERS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.9.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USERS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.10.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USERS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.11.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USERS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.12.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USERS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.13.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USERS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.14.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USERS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.15.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USERS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.16.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USERS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.17.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USERS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.18.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USERS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.19.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USERS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.20.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USERS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.21.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USERS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.22.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USERS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.23.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USERS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.24.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USERS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.25.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USERS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.26.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USERS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.27.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USERS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.28.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USERS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.29.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USERS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY STAGES, 2025-2035 (USD Billion)
  2. 7.30.2 BY AGE GROUP, 2025-2035 (USD Billion)
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USERS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Dry Age-Related Macular Degeneration AMD Market Segmentation

Dry Age-Related Macular Degeneration AMD Market By Stages (USD Billion, 2025-2035)

Early Age-Related Macular Degeneration
Intermediate Age-Related Macular Degeneration
Late Age-Related Macular Degeneration

Dry Age-Related Macular Degeneration AMD Market By Age Group (USD Billion, 2025-2035)

Above 75 Years
Above 60 Years
Above 40 Years

Dry Age-Related Macular Degeneration AMD Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectables

Dry Age-Related Macular Degeneration AMD Market By End Users (USD Billion, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Academic & Research Institutes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035